IMNM (Immunome, Inc.) Stock Financials & Earnings | Market Cap Arena

IMNM (Immunome, Inc.) Stock Financials & Earnings | Market Cap Arena

IMNMImmunome, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$7M

Net Income (TTM)-$212M

EPS (TTM)-$2.43

Free Cash Flow (TTM)-$201M

Gross Margin0.0%

Op. Margin-3228.8%

Net Margin-3060.0%

FCF Margin-2890.1%

P/S Ratio (TTM)277.8x

P/E Ratio (TTM)—

YoY Rev Growth-23.2%

Employees—

Earnings Reports

Next: Q1 2026 · Mar 18

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$2M	-$2M	-$4M
Q2 23	$4M	-$1M	-$6M
Q3 23	$4M	$3M	-$5M
Q4 23	$4M	$4M	-$95M
Q1 24	$1M	$1M	-$132M
Q2 24	$2M	$2M	-$40M
Q3 24	$3M	$3M	-$51M
Q4 24	$3M	$3M	-$83M
Q1 25	$3M	$3M	-$45M
Q2 25	$4M	$3M	-$46M
Q3 25	$0	-$49M	-$60M
Q4 25	$0	$43M	-$73M

Valuation

Quarter	P/S	P/E
Q1 23	815.6x	—
Q2 23	290.9x	—
Q3 23	189.2x	—
Q4 23	137.5x	—
Q1 24	152.0x	—
Q2 24	178.8x	—
Q3 24	190.3x	—
Q4 24	213.3x	—
Q1 25	176.3x	—
Q2 25	153.2x	—
Q3 25	199.2x	—
Q4 25	277.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$24M	$24M
Q2 23	-$6M	-$6M
Q3 23	-$9M	-$9M
Q4 23	-$17M	-$18M
Q1 24	-$11M	-$13M
Q2 24	-$23M	-$26M
Q3 24	-$34M	-$36M
Q4 24	-$42M	-$43M
Q1 25	-$53M	-$57M
Q2 25	-$49M	-$50M
Q3 25	-$41M	-$42M
Q4 25	-$48M	-$52M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$106K
Q2 23	$340K
Q3 23	$36K
Q4 23	$349K
Q1 24	$2M
Q2 24	$2M
Q3 24	$2M
Q4 24	$1M
Q1 25	$4M
Q2 25	$905K
Q3 25	$1M
Q4 25	$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	-41.4%
Q2 23	—	+12.4%
Q3 23	—	-3.9%
Q4 23	—	+1164.7%
Q1 24	-56.5%	+1850.7%
Q2 24	-44.5%	+322.2%
Q3 24	-18.4%	+551.8%
Q4 24	-28.4%	-13.0%
Q1 25	+184.4%	-64.3%
Q2 25	+69.8%	+19.2%
Q3 25	-100.0%	+12.6%
Q4 25	-100.0%	-15.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$1M	51.8%
Q2 23	$1M	24.2%
Q3 23	$1M	30.4%
Q4 23	$3M	75.4%
Q1 24	$2M	209.8%
Q2 24	$3M	136.5%
Q3 24	$5M	168.1%
Q4 24	$5M	199.8%
Q1 25	$6M	194.9%
Q2 25	$5M	133.2%
Q3 25	$7M	—
Q4 25	$8M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$4M	$3M
Q2 23	$6M	$4M
Q3 23	$4M	$4M
Q4 23	$10M	$8M
Q1 24	$15M	$6M
Q2 24	$29M	$7M
Q3 24	$37M	$10M
Q4 24	$48M	$10M
Q1 25	$37M	$11M
Q2 25	$40M	$10M
Q3 25	$49M	$11M
Q4 25	—	$12M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$44M	$0	$44M
Q2 23	$38M	$0	$38M
Q3 23	$91M	$0	$91M
Q4 23	$99M	$39M	$138M
Q1 24	$270M	$40M	$310M
Q2 24	$165M	$113M	$278M
Q3 24	$156M	$85M	$240M
Q4 24	$143M	$74M	$217M
Q1 25	$258M	$60M	$317M
Q2 25	$144M	$124M	$268M
Q3 25	$273M	$0	$273M
Q4 25	$653M	$0	$653M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	12M	+0.4%
Q2 23	12M	+0.1%
Q3 23	12M	+0.0%
Q4 23	22M	+79.9%
Q1 24	10M	-53.0%
Q2 24	60M	+481.4%
Q3 24	60M	+0.4%
Q4 24	63M	+4.2%
Q1 25	79M	+26.6%
Q2 25	87M	+9.6%
Q3 25	88M	+1.1%
Q4 25	87M	-0.7%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$0	23
FY 21	$0	39
FY 22	$0	37
FY 23	$255K	55
FY 24	$77K	118
FY 25	$35	200K